<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04935125</url>
  </required_header>
  <id_info>
    <org_study_id>2525CE</org_study_id>
    <nct_id>NCT04935125</nct_id>
  </id_info>
  <brief_title>The Effects of Endurance and Strength Training in Subjects With Asthma</brief_title>
  <official_title>The Effects of Combined Endurance and Strength Training on Quality of Life in Subjects With Moderate-severe Asthma: a Randomized Controlled Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituti Clinici Scientifici Maugeri SpA</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituti Clinici Scientifici Maugeri SpA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Emerging evidence suggests that regular exercise can complement medical treatment for asthma.&#xD;
      Furthermore there are no specific recommendation on how plan exercise training. To the best&#xD;
      of current knowledge, there isn't enough evidence of the effect of a strength training in&#xD;
      subjects with asthma. Therefore the aim of this study is to evaluate the short and long term&#xD;
      effects of a strength and endurance training compared with endurance training alone in&#xD;
      subjects with asthma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To the best of current knowledge, there isn't enough evidence of the effect of a strength&#xD;
      training in subjects with asthma. Aim of the study is evaluate the short (after pulmonary&#xD;
      rehabilitation) and long term (after 12 months) effects of a strength and endurance training&#xD;
      compared with endurance training alone in improving quality of life and disease control in&#xD;
      subjects with asthma of Global Initiative for Asthma (GINA) stage from 4 to 5.This is a&#xD;
      prospective randomized control trial. Subjects with diagnosis of asthma according to the GINA&#xD;
      guidelines admitted to a reference centre for inpatient pulmonary rehabilitation will be&#xD;
      randomly assigned to study or control group.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 13, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>asthma related Quality of Life</measure>
    <time_frame>4 weeks from enrollment</time_frame>
    <description>Asthma Quality of Life Questionnaire (AQLQ). Range 0 (worst) - 7 (best)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>asthma related Quality of Life</measure>
    <time_frame>1 year</time_frame>
    <description>Asthma Quality of Life Questionnaire (AQLQ). Range 0 (worst) - 7 (best)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Asthma control</measure>
    <time_frame>4 weeks from enrollment</time_frame>
    <description>Asthma Control Questionnaire (ACQ-6). Range 0 (best) - 6 (worst)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eosinophilic airway inflammation</measure>
    <time_frame>4 weeks from enrollment</time_frame>
    <description>Fractional Exhaled Nitric Oxide (FeNO),</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aerobic capacity</measure>
    <time_frame>4 weeks from enrollment</time_frame>
    <description>Maximum oxygen capacity (VO2max) assessed by Cardio Pulmonary Exercise Test, (CPET).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quadriceps and biceps strength</measure>
    <time_frame>4 weeks from enrollment</time_frame>
    <description>Maximal Voluntary isometric Strength (MVS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quadriceps and biceps strength</measure>
    <time_frame>1 year</time_frame>
    <description>Maximal Voluntary isometric Strength (MVS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment satisfaction</measure>
    <time_frame>1 year</time_frame>
    <description>Global Perceived Effect (GPE) score 1 (best) - 7 (worst)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numbers of exacerbations</measure>
    <time_frame>1 year</time_frame>
    <description>number of exacerbations in the last 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asthma control</measure>
    <time_frame>1 year</time_frame>
    <description>Asthma Control Questionnaire (ACQ-6) Range 0 (best) - 6 (worst)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eosinophilic airway inflammation</measure>
    <time_frame>1 year</time_frame>
    <description>Fractional Exhaled Nitric Oxide (FeNO).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aerobic capacity</measure>
    <time_frame>1 year</time_frame>
    <description>Maximum oxygen capacity(VO2max) assessed by Cardio Pulmonary Exercise Test (CPET)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">58</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Standard Program</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>twelve 30-minute daily sessions of supervised incremental exercise training over a period of 3 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Strength training</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>twelve 30-minute daily sessions of supervised incremental exercise training over a period of 3 weeks twelve 30-minute daily sessions of supervised peripheral limb muscle training, 2 set of 6-12 repetitions</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Standard Program + Endurance and Strength training</intervention_name>
    <description>Sessions of strength training added to a standard inpatient multidisciplinary programme</description>
    <arm_group_label>Standard Program</arm_group_label>
    <arm_group_label>Strength training</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Standard Program</intervention_name>
    <description>Standard inpatient multidisciplinary programme (including endurance training)</description>
    <arm_group_label>Standard Program</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of asthma step 4 to 5 under optimal medical treatment for at least 6 months&#xD;
             according to GINA guideline&#xD;
&#xD;
          -  Symptomatic despite being on treatment: Asthma Control Test (ACT) score ≥ 20 ≤24&#xD;
&#xD;
          -  Able to perform and complete with studies procedures (FeNO, CPET, Six Minute Walking&#xD;
             Test (6MWT), MVS.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of Chronic Obstructive Pulmonary Disease (COPD) according to the Global&#xD;
             initiative for Obstructive Lung Disease (GOLD) guidelines criteria&#xD;
&#xD;
          -  Smokers or ex-smokers with pack/years ≥10&#xD;
&#xD;
          -  Body Mass Index (BMI) ≥30&#xD;
&#xD;
          -  Change in asthma medications in the last 30 days&#xD;
&#xD;
          -  Cognitive impairment (Mini-Mental State Examination score &lt;22)&#xD;
&#xD;
          -  History of oncological, neurological, cardiovascular diseases, musculoskeletal&#xD;
             impairment and/or medical diseases precluding exercise testing and pulmonary&#xD;
             rehabilitation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Elisabetta Zampogna</last_name>
    <phone>+39 0331829596</phone>
    <email>elisabetta.zampogna@icsmaugeri.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Antonio Spanevello</last_name>
    <phone>+390331829111</phone>
    <email>antonio.spanevello@icsmaugeri.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Istituti Clinici Maugeri Pneumologia</name>
      <address>
        <city>Tradate</city>
        <state>Lombardia</state>
        <zip>21049</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dina Visca</last_name>
      <phone>+390331829409</phone>
      <email>dina.visca@icsmaugeri.it</email>
    </contact>
    <investigator>
      <last_name>Antonio Spanevello, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 5, 2021</study_first_submitted>
  <study_first_submitted_qc>June 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 22, 2021</study_first_posted>
  <last_update_submitted>September 6, 2021</last_update_submitted>
  <last_update_submitted_qc>September 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>Resistance Training</keyword>
  <keyword>Endurance Training</keyword>
  <keyword>Quality of Life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

